Surveillance Study in Europe and Brazil on Clinical Aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): Implications for Empiric Therapy

• Published in: European urology 2008-11, Vol.54 (5), p.1164-1178
• Main Authors: Naber, Kurt G, Schito, Giancarlo, Botto, Henry, Palou, Juan, Mazzei, Teresita
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Ampicillin; Anti-Bacterial Agents - therapeutic use; Antimicrobial resistance; Bacteria - drug effects; Bacteria - isolation & purification; Brazil - epidemiology; Ciprofloxacin; Cystitis; Cystitis - drug therapy; Cystitis - epidemiology; Cystitis - urine; Drug Resistance, Microbial; Europe - epidemiology; Female; Fosfomycin trometanol; Humans; Incidence; Middle Aged; Nitrofurantoin; Pivmecillinam; Population Surveillance - methods; Prognosis; Prospective Studies; Treatment; Uncomplicated urinary tract infection; Urinalysis; Urology; Uropathogens; Young Adult
• ISSN: 0302-2838; 1873-7560
• DOI: 10.1016/j.eururo.2008.05.010

Abstract Background Uncomplicated cystitis in females is among the most frequent infections in community. Objective To determine clinical aspects, epidemiology, and antimicrobial susceptibility of uropathogens. Intervention Patients were investigated clinically and with urinalysis and urine culture. Measurements This survey started in 2003 and ended in 2006 including 68 centres in nine European countries and in Brazil. Female patients between 18 and 65 yr with symptoms of uncomplicated cystitis were consecutively enrolled and clinically evaluated. Uropathogens were identified and their susceptibility tested for nine antimicrobials. Results and limitations Clinical data of 4264 eligible patients were analysed. A positive urine culture was found in 74.6%. Within the 3018 pathogens, Escherichia coli (E. coli) was most frequent (76.7%), followed by Enterococcus faecalis (4.0%), Staphylococcus saprophyticus (3.6%), Klebsiella pneumoniae (3.5%), and Proteus mirabilis (3.5%). E. coli showed the highest rate of susceptibility to fosfomycin (98.1%) followed by mecillinam (95.8%), nitrofurantoin (95.2%), and ciprofloxacin (91.8%). The lowest rate was found for ampicillin (45.1%). For the total spectrum the order was fosfomycin (96.4%), mecillinam (95.9%), ciprofloxacin (90.3%), and nitrofurantoin (87.0%). In all countries a susceptibility rate to E. coli above 90% was found only for fosfomycin, mecillinam, and nitrofurantoin. The susceptibility rates varied significantly from country to country ( p < 0.0001), except for fosfomycin, mecillinam, and nitrofurantoin. Conclusions Despite wide cross-country variability of bacterial susceptibility/resistance rates to the other antimicrobials tested, fosfomycin, mecillinam, and nitrofurantoin have preserved their in vitro activity in all countries investigated. They may represent good options for the empiric therapy of female patients with uncomplicated cystitis.